Gilead-part­nered Vi­en­na-based im­munother­a­py com­pa­ny Hookipa makes Nas­daq de­but with down­sized $84M IPO

Gilead-part­nered im­munother­a­py de­vel­op­er Hookipa has been work­ing on tech­nol­o­gy us­ing are­navirus­es — a fam­i­ly of virus­es typ­i­cal­ly host­ed by ro­dents — to tur­bocharge the hu­man im­mune sys­tem …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.